Page last updated: 2024-12-08
ferroporphyrin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 193612 |
MeSH ID | M0109482 |
Synonyms (13)
Synonym |
---|
25875-11-0 |
ferroporphyrin |
iron(1+), (7,12-diethenyl-3,8,13,17-tetramethyl-21h,23h-porphine-2,18-dipropanoato(2-)-n21,n22,n23,n24)bis(1h-imidazole-n3)-, (oc-6-13)- |
unii-t978bcy3z4 |
ferrous porphyrin |
t978bcy3z4 , |
3-[18-(2-carboxylatoethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoate;hydron;1h-imidazole;iron(3+) |
ferrate(1-), (7,12-diethenyl-3,8,13,17-tetramethyl-21h,23h-porphine-2,18-dipropanoato(4-)-.kappa.n21,.kappa.n22,.kappa.n23,.kappa.n24)bis(1h-imidazole-.kappa.n3)-, hydrogen (1:2), (oc-6-13)- |
bis(imidazole) protoporphyrin ix iron(iii) |
ferroporphyrin [who-dd] |
ferrate(1-), (7,12-diethenyl-3,8,13,17-tetramethyl-21h,23h-porphine-2,18-dipropanoato(4-)-.kappa.n21,.kappa.n22,.kappa.n23,.kappa.n24)bis(1h-imidazole-.kappa.n3)-, dihydrogen, (oc-6-13)- |
iron(1+), (dihydrogen 3,7,12,17-tetramethyl-8,13-divinyl-2,18-porphinedipropionato(2-))bis(imidazole)-, ion |
ferrate(1-), (7,12-diethenyl-3,8,13,17-tetramethyl-21h,23h-porphine-2,18-dipropanoato(4-)-n21,n22,n23,n24)bis(1h-imidazole-n3)-, dihydrogen, (oc-6-13)- |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (11)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (18.18) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (36.36) | 29.6817 |
2010's | 5 (45.45) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.83
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.83) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |